Syma Iqbal

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients
    Mizutomo Azuma
    University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, The Sharon Carpenter Laboratory, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA
    Pharmacogenomics 8:1705-13. 2007
  2. pmc A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors
    Syma Iqbal
    USC Norris Comprehensive Cancer Center, Oncology, Los Angeles, CA, USA
    Cancer Chemother Pharmacol 72:85-91. 2013
  3. pmc Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
    S Iqbal
    Division of Medical Oncology, University of Southern California, Los Angeles, 90033, USA
    Ann Oncol 22:2610-5. 2011
  4. ncbi request reprint Molecular predictors of treatment and outcome in colorectal cancer
    Syma Iqbal
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3450, Los Angeles, CA 90033, USA
    Curr Gastroenterol Rep 5:399-405. 2003
  5. pmc A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202
    Syma Iqbal
    Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, Rm 3457, Los Angeles, CA 90033, USA
    Cancer Chemother Pharmacol 68:1595-602. 2011
  6. ncbi request reprint Tailored chemotherapy for colorectal cancer: a new approach to therapy
    Syma Iqbal
    University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, Los Angeles, California 90033, USA
    Cancer Invest 22:762-73. 2004
  7. ncbi request reprint Molecular determinants of irinotecan efficacy
    Daniel Vallbohmer
    Divison of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    Int J Cancer 119:2435-42. 2006
  8. doi request reprint Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer
    Oliver A Press
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Cancer Res 68:3037-42. 2008
  9. ncbi request reprint ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan
    Katrin E Rhodes
    Divison of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Drug Metab Lett 1:23-30. 2007
  10. doi request reprint Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin
    Michael A Gordon
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Pharmacogenomics 12:27-39. 2011

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients
    Mizutomo Azuma
    University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, The Sharon Carpenter Laboratory, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA
    Pharmacogenomics 8:1705-13. 2007
    ..e., VEGFA, VEGFR1-3, and neuropilin [NRP]1) are upregulated in metastatic colorectal cancer (mCRC) patients with high serum lactate dehydrogenase (LDH)...
  2. pmc A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors
    Syma Iqbal
    USC Norris Comprehensive Cancer Center, Oncology, Los Angeles, CA, USA
    Cancer Chemother Pharmacol 72:85-91. 2013
    ..At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m(2) with oxaliplatin 130 mg/m(2). ..
  3. pmc Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
    S Iqbal
    Division of Medical Oncology, University of Southern California, Los Angeles, 90033, USA
    Ann Oncol 22:2610-5. 2011
    ....
  4. ncbi request reprint Molecular predictors of treatment and outcome in colorectal cancer
    Syma Iqbal
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3450, Los Angeles, CA 90033, USA
    Curr Gastroenterol Rep 5:399-405. 2003
    ..We discuss the ways in which determination of gene expression levels can enhance the treatment of colorectal cancer through prediction of patient response and tailoring of chemotherapy to the characteristics of an individual tumor...
  5. pmc A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202
    Syma Iqbal
    Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, Rm 3457, Los Angeles, CA 90033, USA
    Cancer Chemother Pharmacol 68:1595-602. 2011
    ..Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days...
  6. ncbi request reprint Tailored chemotherapy for colorectal cancer: a new approach to therapy
    Syma Iqbal
    University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, Los Angeles, California 90033, USA
    Cancer Invest 22:762-73. 2004
    ..The integration of these prognostic and predictive markers would allow individualized treatment for patients, maximizing therapeutic effect and minimizing exposure to toxicity...
  7. ncbi request reprint Molecular determinants of irinotecan efficacy
    Daniel Vallbohmer
    Divison of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    Int J Cancer 119:2435-42. 2006
    ..This small retrospective study suggests that gene expression levels of EGFR, ERCC1 and GST-P1 may be useful in predicting the clinical outcome of patients with metastatic CRC treated with first-line CPT-11 based chemotherapy...
  8. doi request reprint Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer
    Oliver A Press
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Cancer Res 68:3037-42. 2008
    ..This study supports the role of functional EGFR polymorphisms as independent prognostic markers in metastatic colon cancer. As a prognostic factor, these variants had opposite prognostic implications based on gender...
  9. ncbi request reprint ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan
    Katrin E Rhodes
    Divison of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Drug Metab Lett 1:23-30. 2007
    ..The combination of at least one SLCO1B1 521 T allele, one ABCB1 1236 C allele and one UGT1A1*28 variant 7 repeat demonstrated a statistically significant association with Grade 3/4 toxicities in metastatic colorectal cancer patients...
  10. doi request reprint Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin
    Michael A Gordon
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Pharmacogenomics 12:27-39. 2011
    ..There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is dependent on gender...
  11. ncbi request reprint Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer
    Wu Zhang
    Division of Medical Oncology, Department of Preventive Medicine, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 25:3726-31. 2007
    ..We tested the hypothesis of whether these two polymorphisms are associated with sex-specific clinical outcome in metastatic colon cancer patients treated with FU-based chemotherapy...
  12. ncbi request reprint Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab
    Wu Zhang
    Division of Medical Oncology, Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Pharmacogenet Genomics 16:475-83. 2006
    ..004, log-rank test). The findings of this pilot study suggest that the cyclin D1 A870G and the EGF A61G polymorphisms may be useful molecular markers for predicting clinical outcome in CRC patients treated with single-agent Cetuximab...
  13. ncbi request reprint FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
    Wu Zhang
    Division of Medical Oncology, Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 25:3712-8. 2007
    ..We tested the hypothesis of whether these two polymorphisms are associated with clinical outcome in metastatic CRC patients treated with single-agent cetuximab...
  14. ncbi request reprint Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation
    Michael A Gordon
    University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA
    Pharmacogenomics 7:67-88. 2006
    ..e., drug metabolism, tumor microenvironment, cell cycle regulation, and DNA repair) will predict the risk of tumor recurrence in rectal cancer patients treated with chemoradiation...
  15. doi request reprint Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors
    Syma Iqbal
    Department of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA 90033, USA
    Am J Clin Oncol 34:27-31. 2011
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD) of pegylated liposomal doxorubicin (PLD) and docetaxel (T) administered in 4 week cycles in patients with advanced solid tumors...
  16. doi request reprint A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
    Peter M Wilson
    Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cancer Chemother Pharmacol 65:979-88. 2010
    ..We conducted a phase I/II clinical trial to determine the safety and feasibility of combining vorinostat with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (mCRC) and elevated intratumoral thymidylate synthase (TS)...
  17. ncbi request reprint Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer
    Mizutomo Azuma
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Clin Colorectal Cancer 6:214-8. 2006
    ..Our aim was to indicate the frequency of gene expressions of EGFRvIII and EGFR in metastatic colorectal cancer (mCRC)...
  18. doi request reprint Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma
    Deirdre J Cohen
    Division of Medical Oncology, New York University Cancer Center, NYU Medical Center, New York, NY, USA
    Ann Surg Oncol 19:478-85. 2012
    ..However, locoregional recurrences remain high. Accordingly, we instituted this pilot/feasibility study, including intraperitoneal 5-fluoro-2'-deoxyuridine (IP FUDR) as part of the treatment...
  19. doi request reprint Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer
    Georg Lurje
    Division of Medical Oncology, Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA
    Pharmacogenet Genomics 18:161-8. 2008
    ....
  20. ncbi request reprint Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis
    Agustin A Garcia
    University of Southern California Keck School of Medicine, Kenneth Norris Jr Comprehensive Cancer Center, Los Angeles, CA, USA
    Invest New Drugs 24:79-83. 2006
    ..The objective of this phase I study was to determine the maximal tolerated dose (MTD) of the combination of weekly docetaxel and exisulind in patients with advanced solid tumors...
  21. ncbi request reprint Capecitabine: the new generation of fluoropyrimidines in colorectal cancer
    Syma Iqbal
    University of Southern California, Kenneth Norris Comprehensive Cancer Center, Division of Medical Oncology, 1441 Eastlake Avenue, Suite 3457, Los Angeles, CA 90033, USA
    Expert Rev Anticancer Ther 4:947-55. 2004
    ..Ongoing clinical trials are evaluating the efficacy of capecitabine in combination with oxaliplatin and irinotecan as more convenient substitutes for infusional 5-FU in the 5-FU/leucovorin/oxaliplatin and 5-FU/irinotecan regimens...
  22. ncbi request reprint Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule
    Agustin A Garcia
    Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Cancer Chemother Pharmacol 56:75-82. 2005
    ....
  23. ncbi request reprint Molecular determinants of cetuximab efficacy
    Daniel Vallbohmer
    Division of Medical Oncology, Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 23:3536-44. 2005
    ....
  24. ncbi request reprint Angiogenesis inhibitors in the treatment of colorectal cancer
    Syma Iqbal
    Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Semin Oncol 31:10-6. 2004
    ..Other potential targets of angiogenesis, such as the VEGF receptor and multi-targeted agents, are undergoing evaluation in clinical trials...
  25. ncbi request reprint Targeted therapy and pharmacogenomic programs
    Syma Iqbal
    Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Cancer 97:2076-82. 2003
    ..The next step is to develop clinical trials that will assess prospectively the benefits of profiling a patient's particular tumor, which should translate into an improvement in response and toxicity...
  26. ncbi request reprint Integration of novel agents in the treatment of colorectal cancer
    Syma Iqbal
    Kenneth Norris Comprehensive Cancer Center, Division of Medical Oncology, University of Southern California Keck School of Medicine, 1441 Eastlake Avenue, Ste 3457, Los Angeles, CA 90033, USA
    Cancer Chemother Pharmacol 54:S32-9. 2004
    ..The goal in the future will be to predict which specific chemotherapy and targeted agent combination will most likely benefit individual patients...
  27. ncbi request reprint A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels
    Michael V Mandola
    Department of Molecular Biology, The University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Stratford, New Jersey 08084, USA
    Pharmacogenetics 14:319-27. 2004
    ..A 6 bp deletion polymorphism in the thymidylate synthase (TS) gene was investigated in order to determine its function...